Literature DB >> 26007205

Benchmark Outcomes for Pulmonary Valve Replacement Using The Society of Thoracic Surgeons Databases.

Amber D Khanna1, Kevin D Hill2, Sara K Pasquali3, Amelia S Wallace2, Frederick A Masoudi4, Marshall L Jacobs5, Jeffrey P Jacobs6, Tara Karamlou7.   

Abstract

BACKGROUND: As less invasive alternatives to surgical pulmonary valve replacement (PVR) are being refined and evaluated, there is a need for benchmark data concerning outcomes from surgical PVR.
METHODS: We examined in-hospital outcomes from surgical PVR in The Society of Thoracic Surgeons Congenital Heart Surgery Database (STS-CHSD) and Adult Cardiac Surgery Database (STS-ACSD) between 2007 and 2013, with a focus on patients likely to be eligible for transcatheter PVR (ie, ≥ 5 years age and ≥ 30 kg). Patient characteristics, morbidity, and mortality were described.
RESULTS: The STS-CHSD included 6,431 eligible patients with a median age of 17 years (interquartile range [IQR], 14-25 years). Preoperative comorbidities were uncommon: arrhythmia (1.7%), renal failure (0.1%), endocarditis (0.3%), neurologic deficit (0.8%), and diabetes (0.5%). In-hospital mortality was 0.9%. A major complication occurred in 2.2%. The STS-ACSD included 3,352 eligible patients; the median age was 41 years (IQR, 30-55 years). Preoperative comorbidities were more common: arrhythmia (24.3%), renal failure (3.8%), endocarditis (12.2%), cerebrovascular disease (7.9%), and diabetes (10.9%). In-hospital mortality was 4.1%. A major complication occurred in 20.9%.
CONCLUSIONS: Contemporary outcomes from surgical PVR include a low risk of in-hospital death or major complications. Patients in the STS-ACSD are older and have an increased prevalence of preoperative factors, which may contribute to higher morbidity and mortality.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26007205     DOI: 10.1016/j.athoracsur.2015.03.025

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Transcatheter Pulmonary Valve Replacement: Current State of Art.

Authors:  Wail Alkashkari; Amani Alsubei; Ziyad M Hijazi
Journal:  Curr Cardiol Rep       Date:  2018-03-15       Impact factor: 2.931

Review 2.  Pulmonary valve replacement after repaired Tetralogy of Fallot.

Authors:  Hideki Tatewaki; Akira Shiose
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-05-19

3.  Decellularized fresh homografts for pulmonary valve replacement: a decade of clinical experience.

Authors:  Samir Sarikouch; Alexander Horke; Igor Tudorache; Philipp Beerbaum; Mechthild Westhoff-Bleck; Dietmar Boethig; Oleg Repin; Liviu Maniuc; Anatol Ciubotaru; Axel Haverich; Serghei Cebotari
Journal:  Eur J Cardiothorac Surg       Date:  2016-03-24       Impact factor: 4.191

4.  A European study on decellularized homografts for pulmonary valve replacement: initial results from the prospective ESPOIR Trial and ESPOIR Registry data†.

Authors:  Dietmar Boethig; Alexander Horke; Mark Hazekamp; Bart Meyns; Filip Rega; Joeri Van Puyvelde; Michael Hübler; Martin Schmiady; Anatol Ciubotaru; Giovanni Stellin; Massimo Padalino; Viktor Tsang; Ramadan Jashari; Dmitry Bobylev; Igor Tudorache; Serghei Cebotari; Axel Haverich; Samir Sarikouch
Journal:  Eur J Cardiothorac Surg       Date:  2019-09-01       Impact factor: 4.191

5.  Transcatheter pulmonary valve replacement: an option for some but not for all.

Authors:  Chirag Bavishi; Paul C Gordon; Frank W Sellke
Journal:  J Thorac Dis       Date:  2020-11       Impact factor: 2.895

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.